Your browser doesn't support javascript.
loading
Microsatellite instability assessment is instrumental for Predictive, Preventive and Personalised Medicine: status quo and outlook.
Styk, Jakub; Pös, Zuzana; Pös, Ondrej; Radvanszky, Jan; Turnova, Evelina Hrckova; Buglyó, Gergely; Klimova, Daniela; Budis, Jaroslav; Repiska, Vanda; Nagy, Bálint; Szemes, Tomas.
Afiliação
  • Styk J; Institute of Medical Biology, Genetics and Clinical Genetics, Faculty of Medicine, Comenius University, 811 08 Bratislava, Slovakia.
  • Pös Z; Comenius University Science Park, 841 04 Bratislava, Slovakia.
  • Pös O; Geneton Ltd, 841 04 Bratislava, Slovakia.
  • Radvanszky J; Comenius University Science Park, 841 04 Bratislava, Slovakia.
  • Turnova EH; Geneton Ltd, 841 04 Bratislava, Slovakia.
  • Buglyó G; Institute of Clinical and Translational Research, Biomedical Research Centre, Slovak Academy of Sciences, 845 05 Bratislava, Slovakia.
  • Klimova D; Comenius University Science Park, 841 04 Bratislava, Slovakia.
  • Budis J; Geneton Ltd, 841 04 Bratislava, Slovakia.
  • Repiska V; Comenius University Science Park, 841 04 Bratislava, Slovakia.
  • Nagy B; Institute of Clinical and Translational Research, Biomedical Research Centre, Slovak Academy of Sciences, 845 05 Bratislava, Slovakia.
  • Szemes T; Department of Molecular Biology, Faculty of Natural Sciences, Comenius University, 841 04 Bratislava, Slovakia.
EPMA J ; 14(1): 143-165, 2023 Mar.
Article em En | MEDLINE | ID: mdl-36866160
ABSTRACT
A form of genomic alteration called microsatellite instability (MSI) occurs in a class of tandem repeats (TRs) called microsatellites (MSs) or short tandem repeats (STRs) due to the failure of a post-replicative DNA mismatch repair (MMR) system. Traditionally, the strategies for determining MSI events have been low-throughput procedures that typically require assessment of tumours as well as healthy samples. On the other hand, recent large-scale pan-tumour studies have consistently highlighted the potential of massively parallel sequencing (MPS) on the MSI scale. As a result of recent innovations, minimally invasive methods show a high potential to be integrated into the clinical routine and delivery of adapted medical care to all patients. Along with advances in sequencing technologies and their ever-increasing cost-effectiveness, they may bring about a new era of Predictive, Preventive and Personalised Medicine (3PM). In this paper, we offered a comprehensive analysis of high-throughput strategies and computational tools for the calling and assessment of MSI events, including whole-genome, whole-exome and targeted sequencing approaches. We also discussed in detail the detection of MSI status by current MPS blood-based methods and we hypothesised how they may contribute to the shift from conventional medicine to predictive diagnosis, targeted prevention and personalised medical services. Increasing the efficacy of patient stratification based on MSI status is crucial for tailored decision-making. Contextually, this paper highlights drawbacks both at the technical level and those embedded deeper in cellular/molecular processes and future applications in routine clinical testing.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: EPMA J Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Eslováquia

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: EPMA J Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Eslováquia